This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Docetaxel and Immunotherapy Prior to Prostatectomy for High-Risk Prostate Cancer

This study has been terminated.
(Safety reasons, though no safety issues arose.)
Cell Genesys
Information provided by:
Benaroya Research Institute Identifier:
First received: December 18, 2007
Last updated: January 18, 2011
Last verified: November 2010
The purpose of this study is to find out what effects, good and bad, the combination of docetaxel with CG1940/CG8711 (immunotherapy drugs) have on destroying prostate cancer before removal the prostate (prostatectomy).

Condition Intervention Phase
Prostate Cancer Drug: Docetaxel Biological: CG1940/CG8711 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Trial of Neoadjuvant Docetaxel and CG1940/CG8711 Followed by Radical Prostatectomy in Patients With High-Risk, Clinically Localized Prostate Cancer

Resource links provided by NLM:

Further study details as provided by Benaroya Research Institute:

Primary Outcome Measures:
  • Number of Participants With Pathological Complete Response. [ Time Frame: The study evaluates 4 months of docetaxel and immunotherapy prior to radical prostatectomy followed by radical prostatectomy with an additional 3 months of immunotherapy after radical prostatectomy. ]
    CG1940/CG8711 was given along with docetaxel over a series of treatment prior to radical prostatectomy. Pathology of resected specimen was done to determine complete response, defined as no microscopic evidence of neoplastic cells in the resected specimen

Enrollment: 6
Study Start Date: February 2008
Study Completion Date: September 2008
Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Docetaxel
    Docetaxel 75mg/m2 will be given intravenously every 3 weeks for four cycles.
    Other Name: Taxotere
    Biological: CG1940/CG8711
    Immunotherapy allogeneic GM-CSF secreting cellular vaccine

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must have clinical stage 1-3 disease and no radiographic evidence of metastatic disease
  • Nomogram Prediction: Patients must have a Kattan nomogram predicted probability of being free from biochemical progression at 5 years after surgery of <60%.

Exclusion Criteria:

  • Concurrent or prior treatment with radiation, cytotoxic or biologic therapy for prostate cancer, prior hormonal therapy (except finasteride or dutasteride for obstructive voiding symptoms)
  • Male patients unwilling to use effective means of contraception are excluded. Contraception should be continued for 3 months after treatment.
  • Prior malignancy will not exclude the patient. (Patients can not have active cancer or be undergoing active treatment). The Principal Investigator will make final decision regarding eligibility since the end point is pathological complete response.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00577356

United States, Washington
Virginia Mason Medical Center
Seattle, Washington, United States, 98101
Sponsors and Collaborators
Benaroya Research Institute
Cell Genesys
Principal Investigator: Jacqueline Vuky, MD Virginia Mason Medical Center
  More Information

Additional Information:
Responsible Party: Jacqueline Vuky, MD, Virginia Mason Medical Center Identifier: NCT00577356     History of Changes
Other Study ID Numbers: IRB07028
IST# 16194
Study First Received: December 18, 2007
Results First Received: September 13, 2010
Last Updated: January 18, 2011

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action processed this record on August 17, 2017